<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377077</url>
  </required_header>
  <id_info>
    <org_study_id>SNIP punchgrafting study</org_study_id>
    <nct_id>NCT01377077</nct_id>
  </id_info>
  <brief_title>Punchgrafting Techniques for Vitiligo</brief_title>
  <acronym>MiniSNIP</acronym>
  <official_title>Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Punch grafting is a safe, simple and widely used technique for in vitiligo.
      However, no reliable data are available on the effect of punch depth and punch size.

      Objectives: Primary: to compare the efficacy and safety of different punchdepths and
      punchsizes in punch grafting in patients with segmental and non-segmental vitiligo.
      Secondary: to assess the practical aspects and patients preference of different punch
      grafting techniques.

      Study design: Prospective observer blinded randomised controlled study. Study population: 35
      patients â‰¥ 18 years with segmental or stable non-segmental vitiligo who will receive regular
      treatment by punch grafting at the Netherlands Institute for Pigment Disorders (SNIP) at the
      Academic Medical Centre University of Amsterdam.

      Methods: Four depigmented regions on the trunk or upper extremities will be randomly
      allocated to either epidermal 1,5 mm punch grafting, epidermal 1mm punch grafting, dermal 1,5
      mm punch grafting and dermal 1 mm punch grafting. After grafting, all regions will receive
      UV-therapy twice a week for 3 months. Three and six months after grafting, the repigmentation
      of the lesions will be assessed by measuring the outgrowth.

      Main study parameter/endpoint: Outgrowth of pigment after six months.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: The study involves 16 additional punch grafts but no additional visits to our
      institute. Patients will not miss any regular treatment. The extra time due to participation
      in the study will be about 40 minutes. No increase of the risk of side effects is expected by
      placing 16 additional punch grafts. 1.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outgrowth of pigment after six months</measure>
    <time_frame>at 3 and 6 months after treatment</time_frame>
    <description>Objective assessment of the repigmentation 3 and 6 months after punch grafting. Assessment will be done using a ruler on a dermatoscope to measure the diameter of the growth of the punchgrafts. The surface of repigmentation will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual assessment of side effects</measure>
    <time_frame>at 3 and 6 months after treatment</time_frame>
    <description>Visual assessment of side effects (hyperpigmentation, hypopigmentation, scar, cobble stone effect on a scale from 0-3) by a blinded investigator.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Non-segmental Vitiligo</condition>
  <condition>Segmental Vitiligo</condition>
  <condition>Piebaldism</condition>
  <arm_group>
    <arm_group_label>epidermal 1mm grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidermal skin biopsies of 1mm diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dermal 1mm grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dermal skinbiopsies of 1mm diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dermal 1,5mm grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dermal skinbiopsies of 1,5mm diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epidermal 1,5mm grafting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epidermal skinbiopsies of 1,5mm diameter</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>punchgrafting</intervention_name>
    <description>autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions</description>
    <arm_group_label>epidermal 1mm grafting</arm_group_label>
    <arm_group_label>dermal 1mm grafting</arm_group_label>
    <arm_group_label>epidermal 1,5mm grafting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>punchgrafting</intervention_name>
    <description>autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions</description>
    <arm_group_label>epidermal 1mm grafting</arm_group_label>
    <arm_group_label>dermal 1mm grafting</arm_group_label>
    <arm_group_label>dermal 1,5mm grafting</arm_group_label>
    <arm_group_label>epidermal 1,5mm grafting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-segmental and segmental vitiligo under medical treatment at the
             Netherlands Institute for Pigment Disorders

          -  Age between 18 and 60 years

          -  Patient is willing and able to give written informed consent

          -  Vitiligo stable since 12 months without systemic therapy or 6 months without topical
             therapy as defined by the absence of new lesions and/or enlargement of existing
             lesions.

          -  Vitiligo lesions on the extremities or trunk larger than 5x5cm

        Exclusion Criteria:

          -  UV therapy or systemic immunosuppressive treatment during the last 12 months

          -  Local treatment of vitiligo during the last 6 months

          -  Vitiligo lesions with folliculair or non-folliculair repigmentations

          -  Skin type 1

          -  Hypertrophic scars

          -  Keloid

          -  Cardial insufficiency

          -  Patients with a history of hypersensitivity to (UVB) light and allergy to local
             anesthesia.

          -  Patients who are pregnant or breast-feeding

          -  Patients not competent to understand what the procedures involved

          -  Patients with a personal history of melanoma or non-melanoma skin cancer

          -  Patients with a first degree relative with melanoma skin cancer

          -  Patients with atypical nevi.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Netherlands Institute for Pigmentdisorders</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Vrijman, MD</last_name>
      <phone>0031205662575</phone>
      <email>c.vrijman@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Charlotte Vrijman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Albert Wolkerstorfer, MD PhD</name_title>
    <organization>Netherlands Institute for Pigmentdisorders</organization>
  </responsible_party>
  <keyword>vitiligo</keyword>
  <keyword>piebaldism</keyword>
  <keyword>punchgrafting</keyword>
  <keyword>minigrafting</keyword>
  <keyword>stable for at least 12 months</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
    <mesh_term>Piebaldism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

